10-Q: Evolent Health Q1 2026: Revenue Up, Net Loss Widens

Evolent Health reported a 2.6% revenue increase in Q1 2026, driven by new contracts, but saw its net loss widen due to higher claims costs and increased interest expenses.

Summary

• Evolent Health reported total revenue of $496.2 million for the first quarter of 2026, a 2.6% increase from $483.6 million in the same period of 2025.
• The company experienced a net loss attributable to common shareholders of $26.6 million for Q1 2026, compared to a net loss of $72.3 million for Q1 2025.
• Cost of revenue increased by 8.2% to $412.5 million, primarily due to higher claims costs, partially offset by the disposition of Evolent Care Partners (ECP) and decreased personnel costs.
• Selling, general, and administrative expenses decreased by 7.1% to $72.8 million, attributed to lower personnel costs and reduced transaction costs.
• The company's operating loss widened to $10.6 million from $1.6 million in the prior year period.
• As of March 31, 2026, Evolent Health had $142.0 million in cash and cash equivalents and $26.7 million in restricted cash.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to widening operating losses, significantly increased cost of revenue relative to revenue growth, and a deteriorating Medical Expense Ratio, despite a reported increase in total revenue.

Positives

• Total revenue increased by 2.6% to $496.2 million, driven by a new Performance Suite contract go-live.
• Selling, general, and administrative expenses decreased by 7.1% to $72.8 million, indicating improved cost management in these areas.
• The company believes its current cash and cash equivalents are sufficient to meet working capital and capital expenditure requirements for at least the next twelve months.

Negatives

• Cost of revenue increased by 8.2% to $412.5 million, significantly outpacing revenue growth.
• The Medical Expense Ratio (MER) excluding Evolent Care Partners increased to 93.3% from 84.0% in the prior year, indicating higher claims costs relative to revenue.
• Operating loss widened significantly to $10.6 million from $1.6 million in the prior year period.
• Net loss attributable to common shareholders was $26.6 million, although this is an improvement from the prior year's $72.3 million loss, the company is still unprofitable.
• The company faces significant concentration risk with key partners representing substantial portions of revenue and accounts receivable.

Risks

• The significant portion of revenue derived from largest partners, and the potential loss, termination, or renegotiation of these relationships.
• Increasing number of risk-sharing arrangements entered into with partners.
• Growth and success of partners and certain revenues are difficult to predict and subject to factors outside of Evolent's control, including governmental funding reductions and policy changes.
• Ability to accurately predict exposure under performance-based contracts.
• Failure by customers to provide accurate and timely information.
• Ability to recover upfront costs in partner relationships and develop them over time.
• Ability to attract new partners and successfully capture new opportunities.
• Ability to offer new and innovative products and services and keep pace with industry standards, technology, and partner needs.
• Dependency on key personnel and the ability to attract, hire, integrate, and retain them.
• Risks related to completed and future acquisitions, investments, alliances, and joint ventures.
• Ability to effectively manage growth and maintain an efficient cost structure.
• Risks related to managing offshore operations and cost reduction goals.
• Ability to estimate the size of target markets for services.
• Consolidation in the healthcare industry.
• Competition could limit the ability to maintain or expand market share.
• Risks related to audits by CMS and other governmental payers and actions, including whistleblower claims.
• Evolution of the healthcare regulatory and political framework.
• Restrictions on accessing personal data and penalties due to privacy and data protection laws.
• Data loss or corruption due to system failures or service disruptions.
• Liabilities and reputational risks related to safeguarding the security and privacy of confidential data.
• Ability to obtain, maintain, and enforce intellectual property rights and protect trademarks and trade names.
• Ability to protect the confidentiality of trade secrets.
• Risks associated with the use of artificial intelligence (AI) and machine learning models.
• Reliance on third parties and licensed technologies.
• Restrictions on the ability to use, disclose, de-identify, or license data and integrate third-party technologies.
• Reliance on Internet infrastructure, bandwidth providers, data center providers, and other third parties for services.
• Ability to achieve profitability in the future.
• Impact of additional goodwill and intangible asset impairments on results of operations.
• Obligations to make material payments to certain pre-IPO investors for tax benefits.
• Obligations to make payments under the tax receivables agreement that may be accelerated or exceed realized tax benefits.
• Inability to obtain financing may result in a reduction in stockholder ownership.
• Conditional conversion features and changes in accounting treatment of convertible notes.
• Ability to raise funds necessary to settle conversions of notes in cash, repurchase notes, or pay redemption prices.
• Interest rate risk and other restrictive covenants under credit agreements.
• Indebtedness, ability to service indebtedness, and ability to obtain additional financing on favorable terms.
• Interference with the ability to access credit facilities.
• Potential volatility of Class A common stock price.
• Provisions in the certificate of incorporation and by-laws and Delaware law that discourage strategic transactions.
• Provisions in the certificate of incorporation that could limit stockholders' ability to obtain a favorable judicial forum for disputes.
• Intention not to pay cash dividends on Class A common stock.
• Impact of litigation proceedings, government inquiries, reviews, audits, or investigations.
• Public health emergencies, epidemics, pandemics, or contagious diseases.
• Cost of compliance with sustainability or other environmental, social responsibility, or governance laws and regulations.
• Impact of increasing inflationary pressures and rising consumer costs.
• Ability to utilize net operating loss carryforwards and certain other tax attributes may be limited.
• The One Big Beautiful Bill Act (OBBBA) enacted on July 4, 2025, which amends U.S. tax law and makes significant changes to Medicaid, Medicare, and ACA Health Exchanges, potentially reducing members covered by partner health plans.
• The company's significant portion of revenue derived from its largest partners, and the potential loss, termination, or renegotiation of these relationships could have a material adverse effect.

Future Outlook

The company anticipates continued growth in the cost of treatment for cancer and cardiovascular patients, which it expects to be offset in part by contractual protections within its Performance Suite and the impact of its clinical interventions. The company may also seek additional financing for investments, acquisitions, or expansion into other markets.

Management Comments

• The company believes adherence to evidence-based clinical pathways supports better outcomes for patients, a better experience for physicians, and lower costs for the healthcare system overall.
• During 2024, medical claims costs in our Performance Suite grew at a significantly faster rate than historical norms, negatively impacting our financial results. This growth was driven in part by higher disease prevalence, as well as higher cost per active patient. Based on commentary from other market participants, we believe these cost increases were industry-wide and not specific to Evolent.
• Changes in Medicaid, and the ACA Health Exchanges, including but not limited to those caused by the passage of the One Big Beautiful Bill Act during 2025, created industry expectations for higher member acuity and lower membership in future years. These expectations are exacerbated by the aggregate medical trends experienced by our customers across all lines of business, which has led those customers to exit markets, adjust their benefits and take other actions that are likely to contribute to lower membership in the future.
• We believe our current cash and cash equivalents will be sufficient to meet our working capital and capital expenditure requirements for at least the next twelve months as of the date the financial statements were issued.

Industry Context

StockSavvy.ai notes that Evolent Health operates in a challenging healthcare landscape marked by rising medical claims costs and regulatory uncertainty. The company's performance is closely tied to the financial health and strategic decisions of its large health plan partners, and it faces ongoing pressure from industry-wide cost inflation and evolving healthcare policies.

Comparison to Industry Standards

• The Medical Expense Ratio (MER) excluding Evolent Care Partners increased to 93.3% for Q1 2026, significantly higher than the 84.0% reported in Q1 2025. This indicates a substantial increase in claims costs relative to revenue, which is a key concern in the managed care industry.
• Revenue growth of 2.6% is modest compared to some high-growth segments within the healthcare technology and services sector, but it reflects the company's efforts to onboard new contracts.
• The widening operating loss suggests that cost management strategies are not yet fully offsetting the rising operational expenses, particularly claims costs, which is a critical area for profitability in this industry.

Legal Proceedings

• A shareholder derivative action was filed alleging negligence in oversight of the relationship with University Healthcare, Inc. d/b/a Passport Health Plan. The case was dismissed without prejudice, and the Board has refused to initiate litigation as requested by a subsequent shareholder demand.
• The company received a Civil Investigative Demand (CID) from the Department of Justice concerning allegations related to a former customer and unsupported diagnosis codes for Medicare Advantage beneficiaries. The company is cooperating with the investigation.

Related Party Transactions

• Evolent has entered into services agreements with certain equity method investees to provide management, operational, and support services.
• Accounts receivable, prepaid expenses, accounts payable, and accrued liabilities are reported with amounts attributable to unconsolidated related parties.

Stakeholder Impact

• Shareholders: The widening operating loss and continued unprofitability may negatively impact shareholder value. The company's intention not to pay cash dividends in the foreseeable future also affects income-seeking investors.
• Creditors: The company's significant long-term debt of $973.5 million and associated interest expenses could impact its ability to service debt, especially if profitability does not improve.
• Customers (Health Plans): Evolent's reliance on a few large partners creates concentration risk, meaning any adverse changes in these relationships could impact Evolent's services and potentially their own operational stability.
• Employees: The company has implemented cost-saving measures including reduced headcount and changes to bonus structures, which could impact employee morale and retention.

Next Steps

• The company will continue to monitor the impact of broader dynamics on its business and results of operations.
• Evolent will continue to evaluate the expected impact of the One Big Beautiful Bill Act (OBBBA) on its business and financial statements.
• The company may seek additional financing for investments, acquisitions, or expansion into other markets.
• Management will continue to assess goodwill for impairment indicators.

Key Dates

Recommendation

While revenue has increased, the company's operating performance has worsened with a wider operating loss and a significantly higher Medical Expense Ratio. The company remains unprofitable and faces considerable risks related to its large customer concentration and the evolving regulatory environment. The current financial trends suggest a 'hold' recommendation until there is clear evidence of improved profitability and cost control.

Keywords

Evolent Health, 10-Q, Quarterly Report, Healthcare Services, Health Plans, Value-Based Care, Revenue, Net Loss, Claims Costs, Medical Expense Ratio, Performance Suite, SEC Filing